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Background: Sudden cardiac death (SCD) is the clinical outcome of a lethal arrhythmia that can develop on the
background of unrecognized channelopathies or cardiomyopathies. Several susceptibility genes have been
identified for the congenital forms of these cardiac diseases, including caveolin-3 (Cav-3) gene. In the heart Cav-3 is
the main component of caveolae, plasma membrane domains that regulate multiple cellular processes highly relevant
for cardiac excitability, such as trafficking, calcium homeostasis, signal transduction and cellular response to injury. Here
we characterized a new putative Cav-3 variant, Cav-3 V82I, found in a patient with SCD.
Results: In heterologous systems Cav-3 V82I was expressed at significantly higher level than Cav-3 WT and
accumulated within the cells. Cells expressing Cav-3 V82I exhibited a decreased activation of extracellular-signal-regulated
kinases (ERKs) and were more vulnerable to sub-lethal osmotic stress.
Conclusion: Considering that abnormal loss of myocytes can play a mechanistic role in lethal cardiac diseases, we
suggest that the detrimental effect of Cav-3 V82I variant on cell viability may participate in determining the susceptibility
to cardiac death.
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The most challenging type of SCD occurs when it cannot
be traced to any evident cause other than a lethal
arrhythmia, which may represent the sole sentinel event
of an otherwise silent disease [1,2]. Congenital cardiac
channelopathies and cardiomyopathies are known to
play significant roles in SCD [2-4]. In the first cases
genotype-phenotype correlation studies have identified
most of the known disease-causing defects in genes en-
coding cardiac ion channels or other membrane compo-
nents [3], while in the second cases cardiac structural
abnormalities have been detected in subjects carrying
mutations in sarcomeric proteins [4]. However, the iden-
tified variants commonly have reduced penetrance and are
associated with heterogeneous clinical manifestations [2].* Correspondence: s.amoroso@univpm.it
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unless otherwise stated.Such variability in disease expression suggests that other
modifying and triggering causes must be considered [2].
For instance, genetic predisposition and environmental
factors may negatively influence the arrhythmic risk by in-
creasing heart susceptibility to stressing conditions [5-8].
Aberrant cell death can potentially provoke at least three
changes in the heart that are relevant to lethal arrhythmic
processes, namely cardiac contractility compromise, con-
duction disturbance and cardiac remodeling [9-11].
Recent studies have discovered mutations in CAV3
gene encoding caveolin-3 (Cav-3) in subject affected by
hereditary arrhythmias - such as long QT syndrome
(LQTS) and sudden infant death syndrome (SIDS) [12,13] -
or congenital cardiomyopathies [14,15]. Cardiac manifes-
tations are not commonly observed among individuals
affected by caveolinopathies, which often display abnormal
skeletal muscle phenotypes [15-19].
Cav-3 is predominantly expressed in cells experiencing
cyclic mechanical stress (such as striated muscle myocytes)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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These proteins localize within caveolae, plasma membrane
microdomains considered as key platforms for numerous
cellular processes such as endocytosis, lipid metabolism,
mechanosensing and survival response to stressful stimuli
[20-27]. Caveolar membranes contain and regulate different
signalling enzymes, including ERKs (Extracellular-signal-
Regualted Kinases, also known as p44/42 MAP kinases) [28].
Caveolins bind to and negatively regulate ERK activity [28,29].
ERKs can be considered as master regulatory kinases, critic-
ally involved in cell fate determination processes in response
to various stressful stimuli [30]. In particular, alterations in
ERK signalling negatively impact on cell viability under
stressed conditions such as hyperosmotic shock [30,31].
In the present study, we investigated whether a new puta-
tive Cav-3 variant, Cav-3 V82I, found in a patient with SCD
in adulthood, renders cells more vulnerable to osmotic
stress. In particular, we collected evidence that this variant
accumulates within the cell, impairs ERK activation and in-
creases cell death susceptibility to sub-lethal osmotic stress.
Methods
Analysis of sequence
Genomic DNA was extracted by phenol/chloroform
from peripheral blood, obtained after informed consent
from 50 unrelated patients with suspected or diagnosed
LQTS, for which a genetic screening was requested by
cardiologists for definitive diagnosis. No mutations were
found in the entire coding regions of the major LQTS
associated genes (KCNQ1, KCNH2, SCN5A, KCNE1,
KCNE2, and KCNJ2) and in ANK2 and RyR2 genes [3,4].
DNA was submitted to open reading frame/splice site mu-
tational analysis on CAV3 gene by PCR and direct DNA
sequencing, using coding region flanking primers (Table 1).
PCR was performed in a final volume of 25 μl containing
1X Buffer, 1.5 mM MgCl2, 1 μM each primer, 0.2 mM
each dNTP, 2.5 U Taq polymerase (all from Euroclone,
Milan, Italy) and 10 ng of DNA template. PCR was per-
formed on a 9700 thermal cycler (Applied Biosystems,
Monza, Italy) and involved 1 cycle at 95°C for 5 min,
followed by 35 denaturation cycles at 94°C for 30 sec, an-
nealing at 57°C for 30 sec, extension at 72°C for 30 sec and
a final extension at 72°C for 10 min. Primers for sequencingTable 1 Primers used for CAV3 PCR and sequencing
reaction






Cav3_2.2R GTGGAGAGGTTGGCCCCreaction were the same of PCR. Sequencing reaction was
performed using BigDye terminators ready reaction kit
(Applied Biosystems, Monza, Italy) according to manufac-
turer’s protocol. Sequencing products were submitted to CE
on Applied Biosystems 3130 Genetic Analyzer. Sequences
were aligned and compared with the Cav-3 reference
sequence NM_033337 in GenBank by Seqscape software
v2.5.0 (Applied Biosystems, Monza, Italy).
All experiments were carried out in strict accordance
with the Clinical Practice Guidelines of A.O.U. “Ospedali
Riuniti di Ancona”, and with the Oviedo Convention on
Human Rights and Biomedicine, ratified by Italian law
145 of 28 March 2001.
Site-direct mutagenesis
Plasmid containing Cav-3 wild-type cDNA was purchased
from Origene. In vitro site-direct mutagenesis was
performed by QuickChange Site-Direct Mutagenesis
kit (Agilent Technologies, Milan, Italy) following manu-
facturer’s instructions. The presence of the G244A muta-
tion (V82I) was confirmed by sequence analysis.
Cell culture
BHK cells were cultured in a humified 5% CO2 atmosphere
in DMEM supplemented with 10% fetal bovine serum,
6 mM glutamine, 1 mM pyruvate, 100 U/ml penicillin and
100 μg/ml streptomycin. For immunofluorescence studies,
cells were plated on glass coverslips 16 h before transfection.
Transient transfection and western blot
The plasmids containing respectively the Cav-3 WT and
Cav-3 V82I were transfected to BHK cells with Attractene
(Qiagen, Milan, Italy) following manufacturer’s instructions.
Transfection efficiency, quantified by co-transfecting Cav-3
and EGFP expressing plasmids, was ~70-80% both for the
WT and mutant. Twenty-four hours post transfection,
whole cell lysates for western blot analysis were obtained
using a cell lysis solution containing (in mM): NaCl, 150;
Tris–HCl (pH 7.4), 10; EDTA (pH 8.0), 1; SDS 1%, and a
protease inhibitor cocktail mixture. All samples were pre-
pared in buffer containing SDS and 2-mercaptoethanol
and boiled at 100°C for 10 min prior to loading. Im-
munoblotting on 8% polyacrylamide was performed as
described previously [32] and the following primary
antibodies were used: mouse anti-CAV3 (1:500), purchased
from Santa Cruz Biotechnology (Santa Cruz, California,
USA) and mouse anti-tubulin (1:10000; Sigma). The band
images were digitally captured and band intensities were
quantified using a ChemiDoc station and the Quantity
one analysis software. The relative amount of caveolin-3
protein was normalized on tubulin. In some experiments,
10 μg/ml cycloheximide (stock solution 100 mg/ml in
DMSO; Millipore, Billerica, MA, USA) was added directly
to BHK cells 24 h after transfection with Cav-3 WT or
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was determined by collecting cell lysates at the indicated
time points [33,34].
Caveolin-3 Triton solubility
Caveolin-3 partitions into Triton-soluble fraction were
determined 24 h after transfection with the indicated
plasmid as described before [14,35,36]. Briefly, transfected
BHK cells were washed twice with ice-cold PBS and lysed
for 30 min on ice in 1% Triton X-100 buffer (pH 6.5) con-
taining 150 mM NaCl, 25 mM MES, protease inhibitors.
Samples were then centrifuged at 14,000 × g for 10 min at
4°C and pellet (the insoluble fraction; I) and supernatant
(soluble fraction; S) were resolved and analyzed by
caveolin-3 immunoblotting as described before.
Immunofluorescence microscopy
24 hours after transfection, BHK cells plated on glass
coverslips were washed with PBS and fixed for 15 min
with ice-cold PBS 4% paraformaldehyde, 2% sucrose.
Cells were then incubated with PBS 3% BSA and 0.1%
Triton for 30 min at RT and following incubated over
night with the mouse antibody anti-Cav-3 (Santa Cruz
Biotechnology) 1:500 in PBS 3% BSA. Finally, cells were
incubated for 1 h in the dark with the Alexa Fluor 488
anti-mouse IgG (Invitrogen, Monza, Italy) 1:500 in PBS
3% BSA and then analyzed on a Zeiss LSM510 META
confocal microscope (Zeiss, Arese, MI, Italy). For Nile
red staining, the dye was added directly to fixed cells
(1:100 dilution in PBS from a 1 mg/ml stock solution in
acetone) after Cav-3 immunolabelling, and samples were
incubated in the dark for 10 min at room temperature.
Determination of mitochondrial activity and cell death
Mitochondrial activity was quantified by measuring de-
hydrogenase activity retained in the cultured cells, using
the MTT assay [37]. The assay is based on the ability of
living cells to convert dissolved MTT into insoluble
formazan. Briefly, 24 h after transfection, BHK cells
were washed with PBS and treated for 30 min in the
cell culture incubator with 1 ml culture medium or
mannitol solution (1.1 M in culture medium). After an
additional wash with PBS, cells were then incubated with
1 ml of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) solution (0.5 mg/ml in PBS). After
1 h incubation at 37°C, cells were finally washed with PBS
and the formazan produced was dissolved in 1 ml of
dimethylsulfoxide (DMSO). The absorbance was read at
540 nm. Data were expressed as the percentage of cell in-
jury to sham-treated cultures.
To evaluate cell death under basal and mannitol stress
conditions, cells were treated as described above and
then double stained with 36 μM Fluorescein diacetate
and 7 μM Propidium iodide for 20 min at 37°C in PBS.Stained cells were examined immediately with a standard
inverse fluorescence microscope and analyzed as described
before [38].
Determination of ERK activity
ERK activity was evaluated by in vitro phosphorylation
of Elk-1 protein (an ERK substrate) in cell lysates using
a commercially available nonradioactive assay kit (Cell
Signaling, Boston, MA, USA). Briefly, 1 × 106 BHK cells
were plated into 100 mm dishes 16 h before transfection
with EGFP, Cav-3 WT or Cav-3 V82I expressing vectors.
Transfected cells were exposed to standard or mannitol-
containing culture media as previously described. pERK
affinity precipitation was performed incubating cell ex-
tracts (overnight at 4°C) with sepharose bead conjugate
phospho-p44/42 MAP Kinase monoclonal antibody. The
immunoprecipitates were then used in an in vitro kinase
assay using Elk-1 as substrate. pERK activity was finally
evaluated quantifying by immunoblotting the level of
Elk-1 phosphorylation with anti-phospho-Elk-1 (pElk)
mouse antibody.
Since the doubly phosphorylated forms of ERK repre-
sent the active enzymes, we also used anti-phospho-ERK
immunoblotting as direct ERK activation marker. To de-
tect the active form of ERKs, cell lysates were subjected
to western blot analysis using pERK and ERK antibodies
(Santa Cruz, California, USA). The amount of ERK phos-
phorylation was quantified by densitometry and normalized
by expressing the data as a ratio of pERK over the total
ERK.
Statistical analysis
Data were analysed by t-test for paired or unpaired data as
appropriate. For multiple group comparisons, two way
ANOVA followed Dunnett post-hoc test was used as
appropriate.
Chemicals
All the other chemicals were of analytical grade and were
purchased from Sigma, Italy.
Results
Identification of a novel CAV3 mutation
Sequencing analysis of CAV3 gene in 50 probands with
suspected or diagnosed LQTS identified 9 single nucleo-
tide variations (SNVs), 3 on the exon 1 amplicon and 6
on the exon 2 amplicon. Five SNVs were localized in the
flanking region of exon 1 and exon 2 and were not con-
sidered in this study. The remaining four SNVs (C27T
corresponding to SNP rs1974763, C99T to rs1008642,
T123C to rs13087941 and G244T to rs112626848) were
found in the coding region of the CAV3 gene; three
of them (rs1974763, rs1008642 and rs13087941) were
synonymous mutations with no pathogenic implications;
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at nucleotide 244 (G > A) (Additional file 1) leading to
amino acid change, valine to isoleucine, at codon 82
(V82I), involving a residue conserved across several spe-
cies in the transmembrane domain (Figure 1 and [12]).
Expression and distribution of wild type and V82I mutant
of Caveolin-3
To investigate the impact of V82I mutation on Cav-3
protein level and cellular localization, we introduced the
V82I substitution detected in the patient into the human
Cav-3 WT sequence. We next transfected BHK cells with
Cav-3 WT or Cav-3 V82I and compared levels of wild-
type and mutant in SDS lysates, which represent the total
caveolin-3 pool. As shown in Figure 2, Cav-3 V82I mutant
was expressed at significantly higher level (about 1.4 fold)








Figure 1 Caveolin-3 topological domains and localization of the V82I
organization of the caveolin-3 protein. Numbers above the line indicate am
domains (23): N-terminal (aa 1–53), scaffolding (aa 54–73), transmembrane
residue within the transmembrane domain. (b) Sequence alignment of cav
modifies a conserved amino acids in caveolin-3.protein caused by V82I mutation is somehow a new
finding since most of caveolin-3 mutations often cause a
severe loss of Cav-3 protein [19]. To examine whether
differences in protein stability between WT or V82I mu-
tant accounted for the higher expression level of Cav-3
V82I, we performed cycloheximide (CHX) block experi-
ments [33,34]. WT or V82I transfected BHK cells were
treated with CHX for 1–6 h to inhibit protein synthesis,
harvested at different time points, and resulting ly-
sates were probed with anti-Cav-3 antibody to monitor
caveolin-3 levels, or anti-tubulin antibody as a loading
control. As shown in Figure 3, during CHX chase, Cav-3
WT protein declined over time, decreasing to 70% levels
by 6 h, while Cav-3 V82I levels were significantly more
stable over the 6 h time course. These results suggest that
V82I mutation confers increased stability to caveolin-3
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Figure 2 Recombinant expression of Cav-3 WT and Cav-3 V82I. (a) BHK cells were transiently transfected with either Cav-3 WT or Cav-3 V82I
expressing plasmids. Twenty-four hours after transfection, cells were lysed and subjected to western blot analysis using anti-caveolin-3 antibody.
The mutant form was expressed at significantly higher level than achieved with the wild-type caveolin-3. (b) Quantization revealed that Cav-3
V82I was expressed at about 40% the expression level observed for Cav-3 WT. Data are representative of 15 independent experiments
(*** P < 0.001).
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interesting to note that 1 h of CHX treatment significantly
increased the expression of the V82I mutant (but not of
the WT form): the reason of such increase is currently
unknown.
We further investigated the sub-cellular distribution of
wild type and mutant V82I caveolin-3 by means of con-
focal microscopic analysis. In BHK cells, the wild type
caveolin-3 was localized both at the plasma membrane
and within the cells, while Cav-3 V82I was mainly retained





Figure 3 Stability of Cav-3 WT and Cav-3 V82I. Transfected BHK cells w
length of time. Cells were then collected in same volumes of lysis buffer an
Representative blot is shown in (a). Levels of residual caveolin-3 at the indi
in (b). Data are representative of four independent experiments. *, P < 0.05
time points.Z-stack image series). In most cells, a ring-like labelling
was also observed, especially for Cav-3 V82I mutant
(Figure 4). These intracellular structures stained with
the Cav-3 antibody varied in size and were often clus-
tered together. To determine whether these spherical
structures were the so-called lipid bodies (LB), organelles
targeted by caveolins (both wild types and mutant forms)
[34,39,40], we carried out double-labelling analysis with
antibodies to caveolin-3 proteins and with Nile red, a
marker for LB [34,39,40]. As reported in Figure 5, both

























ere treated with cycloheximide (10 μg/ml; CHX) for the indicated
d equal volumes of extracts were analyzed by immunoblotting.
cated time points (% of time 0) for Cav-3 WT and Cav-3 V82I are shown




Figure 4 Immonolocalization of Cav-3 WT and Cav-3 V82I. BHK cells were transiently transfected with Cav-3 WT (a) or Cav-3 V82I (b) and
immunostained with the antibodies against caveolin-3 followed by Alexa Fluor 488 conjugated secondary antibodies. Cav-3 V82I mutant was
retained intracellularly and not properly targeted to the plasma membrane as Cav-3 WT (arrowheads). Vesicular-like structures (LB) stained with
the caveolin-3 antibodies were also observed, especially for Cav-3 V82I mutant (arrows); Scale bar: 10 μm. Four independent transfected cultures
were analyzed.
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Nile red stained vesicles. However, we found that not all
the Cav-3 positive structures were also positive for Nile
red, as well as that some LB were stained only with Nile
red. Similar results were obtained in a rat cardiomyoblast
cell line, H9c2 cells (Additional file 3), suggesting that the
observed differences in protein expression between Cav-3
V82I and WT forms were not related to the cell type used.V82I 
WT 
Cav-3 N
Figure 5 Colocalization analysis of Cav-3 WT and Cav-3 V82I with the
antibodies followed by Alexa Fluor 488 conjugated secondary antibodies. LBs
stock solution in acetone). BHK cells expressing Cav-3 V82I (bottom) showed
(top). Scale bar: 5 μm (2.5 μm in the inserts). Two independent transfected cuIt has been reported that unstable Cav-3 mutants,
usually characterized by a marked reduction in their
expression and retained in the Golgi complex [15,19,35,36],
are expressed at higher levels and accumulate within the
endoplasmic reticulum (ER) after treatment with prote-
asome inhibitors [41]. Considering that the V82I mutation
increased Cav-3 expression and that LB have an ER origin
[39], we sought to investigate whether the distribution ofile red Merge 
LB marker Nile red. Cav-3 transfected cells were labeled with Cav-3
were then stained with Nile red (1:100 dilution in PBS from 1 mg/ml
a marked localization in LB structures (bottom) as compared to Cav-3 WT
ltures were analyzed.
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of the protein in the ER. To address this hypothesis,
transiently transfected BHK cells were subjected to
double labeling with antibodies directed against caveolin-3
and calnexin, an ER specific marker protein [42]. Despite
the increased expression and intracellular caveolin-3 re-
tention observed in Cav-3 V82I transfected cells, V82I
mutant was not distributed to ER since no significant
colocalization was observed between V82I and calnexin
(Figure 6). In cells transfected with the WT form,
caveolin-3 was mostly expressed at cell surface and did
not colocalize with calnexin (Figure 6), in line with
previous results [41].
We next characterized the biochemical properties of
the Cav-3 V82I assessing its detergent solubility pattern.
Caveolins mainly reside within caveolar lipid rafts which
are insoluble in non-ionic detergents such as Triton
X-100, while several caveolin-3 mutants with decreased
surface expression usually display an increased Triton
X-100 solubility [14,35,36]. By western blot analysis we
found that in Cav-3 WT transfected cells caveolin-3
protein was mainly distributed in the Triton-insoluble
fraction (I) (Figure 7), consistent with data reported be-
fore [36,43]. For Cav-3 V82I, we observed a significant
increased of caveolin-3 expression both in the Triton-
insoluble and in the Triton-soluble (S) fractions (respect-
ively 2.6 and 3.5 fold as compared to WT; Figure 7). The
increased distribution of Cav-3 V82I in the Triton-soluble
fraction (expressed as caveolin-3 soluble/pellet ratio) wasCav-3 C
WT 
V82I 
Figure 6 Colocalization analysis of Cav-3 WT and Cav-3 V82I with the
WT (top) or Cav-3 V82I (bottom) and subjected to double labelling with an
in the merged images, no significant colocalization with calnexin was obse
representative of three independent cultures.not statistically different (42.4 ± 10.1% vs 29.1 ± 5.9%, V82I
vs WT, respectively; n = 5, P = 0.29).
Effect of Cav-3 V82I on ERK activity and cell viability
As previously reported, caveolin proteins negatively regu-
late ERK activity [28,29,44]. Considering that cell viability
is compromised when ERK signalling pathways are dis-
rupted [30,31], we first tested the effects of Cav-3 V82I on
ERK activation. Lysates from BHK cells transfected, either
with Cav-3 WT or Cav-3 V82I, were analyzed by western
blot using specific monoclonal antibodies directed against
total ERKs or their phosphorylated (active) form. Both
Cav-3 WT and Cav-3 V82I did not modify total ERK
expression. On the contrary V82I mutant significantly
impaired both basal and mannitol-stimulated ERK acti-
vation as compared to Cav-3 WT (Figure 8). Similar
results were obtained when we measured p44/42 MAP
kinase activity using a nonradioactive assay kit that detects
the specific phosphorylation of the p44/42 MAP kinase
substrate Elk-1 (Figure 8). Interestingly, cells transfected
with Cav-3 V82I were more vulnerable to the mannitol
challenge used to activate ERK, since both mitochondrial
activity (measured by MTT assay) and cell viability
(measured by the Propidium/Fluoroscein assay) were sig-
nificantly affected (Figure 9).
Discussion
In this report, we identified and characterized a novel
heterozygous mutation in caveolin-3 gene. This mutationalnexin Merge 
ER marker calnexin. BHK cells were transiently transfected with Cav-3
tibodies raised against caveolin-3 (green) and calnexin (red). As shown
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Figure 7 Cav-3 V82I partitions into Triton-soluble (S) and Triton-insoluble (I) cell fractions. Twenty-four hours after transfection, the
Triton-soluble and insoluble fractions were collected from Cav-3 WT and Cav-3 V82I transfected BHK cells as described in Materials and Methods.
Equal volumes of the soluble and insoluble fractions were analyzed by immunoblotting. Representative blot is shown in (a). Cav-3 V82I was
significantly more abundant than the WT both in the S and in the I fractions (b). Data are representative of five independent experiments.
**, P < 0.01 V82I vs WT in the soluble fraction; ***, P < 0.001 V82I vs WT in the insoluble fraction.
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LQTS who suddenly died prior to completion of com-
prehensive cardiological examination. No mutations
were found in the entire coding regions of the major
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Figure 8 Effects of Cav-3 WT or Cav-3 V82I expression on ERK1/2 acti
V82I. (a) Cell lysates were subjected to SDS-PAGE and analyzed by immuno
cellular level of ERK remained unaltered after the transfection with either C
significant decrease in pERK (active form) was observed in the presence of
hyperosmotic stress with mannitol. (b) Quantization revealed that in Cav-3
as compared with Cav-3 WT and mock transfected cells. Data are represen
mock and Cav-3 WT groups. Similar results were obtained in (c,d). Cell lysates
ERK1/2 kinase assay as described in Materials and Methods. Representative blo
(d). Data are representative of three independent cultures. *, P < 0.05 V82I vs WKCNE1, KCNE2, and KCNJ2) and in ANK2 and RyR2
genes [2,3].
Valine-to-isoleucine substitution is considered as a con-
servative change in that the two amino acids differ by only
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vation. BHK cells were transiently transfected with Cav-3 WT or Cav-3
blotting using anti-ERK and anti-pERK antibodies. Expression of total
av-3 WT or Cav-3 V82I in all the conditions tested. On the contrary, a
the caveolin-3 mutant, both under resting conditions and after 30 min
V82I expressing cells there was a significant decrease of ERK activation
tative of three independent experiments. **, P < 0.01 vs the respective
from control and mannitol treated groups were subjected to an in vitro
t is shown in (c) and relative band intensities of pElk analysis is shown in

























- mannitol + mannitol 
- mannitol 
+ mannitol 
Mock WT V82I 
a 
b 
Figure 9 Effects of Cav-3 WT or Cav-3 V82I expression on cells viability. BHK cells were transiently transfected with Cav-3 WT or Cav-3 V82I
and mitochondrial activity and cell death were evaluated by MTT and Propidie/Fluorosceine assays, respectively. (a) Expression of Cav-3 WT or
Cav-3 V82I did not modified mitochondrial function under basal conditions. On the contrary, a significant decrease of mitochondrial activity was
observed in Cav-3 V82I expressing cells subjected to hyperosmotic stress. Data are representative of five independent experimental sessions.
*, P < 0.05. (b) Images show the intravital staining that yields green yellow fluorescence for vital cells and red fluorescence for dead cells under
basal and hyperosmolar conditions. Images are representative of three independent experiments.
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ever, despite their similarity, their side-chains differ in size,
shape and hydrophobicity, and these differences account
for the fact that valine and isoleucine are not always
interchangeable in proteins [45]. Moreover, V82I mutation
alters a conserved amino acid of the Cav-3 membrane-
spanning segment (Figure 1 and [12]).
In humans, the majority of caveolinopathies often refers
to a wide spectrum of skeletal muscle disorders [19,46]
and only recently mutations in caveolin-3 were associated
to cardiac pathologies including LQTS and SIDS [12,13]
and cardiomyopayhies [14,15]. Several mechanisms have
been proposed for the skeletal muscle degenerative pro-
cesses, whereas the molecular bases for the cardiac pheno-
types are largely unknown [14,19,46].
Biochemical analysis of transiently transfected cell line
showed that Cav-3 V82I is expressed at higher level than
Cav-3 WT (Figure 2 and Additional file 3) probably as
consequence of higher protein stability as revealed by
CHX assay (Figure 3). Moreover, V82I mutant did not
alter the detergent solubility of caveolin-3 protein, and a
significant increase of caveolin-3 expression was foundboth in the Triton-insoluble (I) and in the Triton-soluble
(S) fractions (Figure 7). These results are in strike contrast
to the majority of the known caveolin-3 mutants which
cause 1- severe loss of protein, 2- decrease of protein half-
life, 3- increased expression in the Triton-soluble fraction
[14,19,35,36,41].
To study the functional alterations of Cav-3 due to
V82I mutation, we examined the intracellular distribution
of the mutant protein by confocal microscopy. Immuno-
fluorescence studies revealed that Cav-3 V82I tends to
accumulate within the cells, suggesting that the V82I mu-
tation affects a critical residue required for correct cell
surface expression as observed with caveolin-3 WT
(Figures 4, 5, 6 and Additional files 2, 3). It is interest-
ing to note that the threonine 78, a residue very close
to the valine 82, is also critical for proper targeting of
caveolin-3 protein to the plasma membrane, since Cav-3
T78K (but not Cav-3 T78M) mutant fails to distribute to
cellular surface [15]. The retention in intracellular com-
partments is a common phenotype observed with different
pathogenetic caveolin-3 mutants that often form aggre-
gates within Golgi complex [15,19,35,36,41,47]. In contrast
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distribution, characterized by reduced targeting to the
plasma membrane and, in most transfected cells, by in-
creased staining of ring-like LB structures (Figures 4, 5
and Additional files 2, 3). A very similar labelling pattern
was reported for Cav-3DGV, an amino-terminal truncation
mutant of caveolin-3, which fails to reach plasma mem-
brane and highly localizes into LB [40,47]. Since Cav-3
V82I mutant is not properly distributed to cell surface, we
suggest that Cav-3 V82I found in the Triton insoluble
fraction does not primarily come from plasma membrane
caveolae/lipid rafts but instead from intracellular com-
partments such as LB where Cav-3 V82I accumulates
(Figure 5). To this regard, it is interesting to note that
Cav-3DGV LB pool is Triton-insoluble [40].
When proteasome activity is inhibited, intracellular
retained and unstable Cav-3 mutants are expressed at
significantly higher level and display a characteristic
redistribution to ER (but not to plasma membrane)
[41]. Considering that V82I mutation increased Cav-3
cell expression and that LBs have an ER origin [39], we
hypothesized that Cav-3 V82I would also display a
similar ER retention. However, no significant accumu-
lation of Cav-3 V82I protein was observed within the
ER (Figure 6).
Several studies have proposed a critical role for
caveolin-3 in cell life and death decision mechanisms.
In fact, when caveolin-3 dependent signalling pathways
are disrupted, critical cellular functions are significantly af-
fected, including proliferation [47], survival response to
stressful stimuli [22], preservation of plasma membrane
integrity during mechanical stresses [24] or toxin-induced
membrane injury [27]. Based on these findings, we com-
pared the survival response to brief hyperosmotic stress
elicited in cells transfected with Cav-3 WT or with Cav-3
V82I. Under resting conditions, neither WT nor V82I
form had any effect on cell viability (Figure 9). However,
V82I mutant significantly increased cell death susceptibil-
ity under a mannitol stress that was sub-lethal in Cav-3
WT transfected cells (Figure 9). Such increased cell
vulnerability may be related to the altered caveolin-3
distribution observed in Cav-3 V82I transfected cells
(Figures 4, 5). In fact, the reduced plasma membrane
targeting of V82I mutant would impair caveolae formation
(a process that require caveolin protein) and consequently
affect caveolae-mediated protective response to plasma
membrane stress [24,27].
Since ERK signalling pathways are regulated by Cav-3
proteins [48] and influence the survival rate of the cells
[30,49], we also explored the effect of Cav-3 V82I on
ERK activation. We found that V82I significantly reduced
ERK activation both under resting condition and after
hyperosmotic stress (Figure 8). The negative effects on
ERK activation exerted by V82I mutant may be simplyrelated to the higher caveolin-3 expression level observed
in Cav-3 V82I transfected cells. Collectively, our data sug-
gest that the expression of Cav-3 V82I is detrimental for
the survival response to mechanical stress.
Signs of apoptosis among myocytes have been docu-
mented as characteristic histological signature in various
arrhythmic patients [11,50,51] and abnormal cardiomyo-
cyte death may be clinically relevant for the development
of life-threatening arrhythmia in terms of associated (if
not causative) mechanism [9-11,50,51]. It is interesting to
note that for Cav-3 the so-called “TFT mutation” causes
apoptosis in skeletal muscle cells [52] and decreases
myotube resistance to oxidative stress [22]. In connec-
tion to these data, we propose that the Cav-3 V82I
variant increases cell vulnerability to stress conditions
and may participate in determining the susceptibility
to cardiac death.
The sodium/calcium exchanger 1 (NCX1) is an electro-
genic cardiac Ca2+ transporter protein that regulates car-
diac excitation-contraction coupling [53]. NCX1 normally
contributes to the ion currents responsible for the action
potential but can trigger arrhythmias under pathological
conditions [53]. Based on previous data showing Cav-3/
NCX1 interaction [54], we hypothesize that Cav-3 V82I
could also affect NCX1 activity. However, in biochemical
and functional experiments using BHK cells stable ex-
pressing NCX1, we found no interaction between NCX1
and WT or V82I Cav-3 (Additional file 4).
Conclusions
The biochemical and functional findings presented here
provided evidence that the new putative caveolin-3 V82I
variant discovered in our patient has a cell expression
profile significantly different not only from the WT form
(Figures 2, 3, 4, 5, 6, 7, 8, 9 and Additional files 2, 3)
but also from most of the mutants analyzed so far
[14,15,19,35,36,41,47]. Cells expressing Cav-3 V82I dis-
played altered caveolin-3 distribution and were more
vulnerable to sub-lethal osmotic stress. These defects
may potentially be of clinical relevance considering that
abnormal loss of myocyte can deadly impair people’s
health [9-11,50,51].
Some Cav-3 mutants have been reported to influence
the activity of ion channels localized within caveolae
[12,13,55], but it is still not fully understood whether
and how these mutants impact on the action potential
as a whole [56,57]. Therefore, we cannot exclude the
possibility that Cav-3 V82I may alter the currents car-
ried by these channels and further work is required to
address this issue. However, we provided evidence that
the V82I mutant has no effect on NCX1, a key plasma
membrane transporter that under normal and patho-
logical conditions influences multiple properties of cardi-
omyocytes, including cell excitability [53].
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Additional file 1: Identification of the missense mutation in Cav-3
gene. Electropherograms show partial Cav-3 sequences from control
subject (top) and the index patient (bottom). The arrows indicate the
heterozygous nucleotides of G/A in the proband or the homozygous
nucleotides of G/G in unrelated normal control.
Additional file 2: Characterization of Cav-3 WT and Cav-3 V82I
expression in BHK cells. The figure shows the complete Z-stack
series of Cav-3 WT (a) and Cav-3 V82I (b) transfected BHK cells
reported in Figure 2. ~4 μm optical slice thickness, 5 z-sections
collected at 1 μm intervals. Scale bar: 10 μm.
Additional file 3: Characterization of Cav-3 WT and Cav-3 V82I
expression in H9c2 cells. (a) H9c2 cells were transiently transfected with
either Cav-3 WT or Cav-3 V82I. Twenty-four hours after transfection, cells
were lysed and subjected to western blot analysis using anti-caveolin-3
antibody. The mutant form was expressed at significantly higher level
than achieved with the wild-type caveolin-3. The blots are representative
of 4 separate experiments. (b) In Cav-3 V82I transfected cells, caveolin-3
protein was located mainly in ring-shaped LB as revealed by
immunofluorescence analysis. Scale bar: 5 μm. Data are
representative of 2 independent transfected cultures.
Additional file 4: Analysis of Cav-3 WT and Cav-3 V82I interaction
with NCX1 in BHK cells. (a) Stable NCX1 expressing BHK cells were
transiently transfected with EGFP, Cav-3 WT or Cav-3 V82I. Twenty-four
hours after transfection, cells were lysed and subjected to western blot
analysis using anti-NCX1 antibody. No difference in NCX1 expression was
seen between the three transfected groups (the blot is representative of
3 separate experiments). (b) NCX1 was not associated with Cav-3 WT or
Cav-3 V82I as determined by co-immunoprecipitation (the blots are
representative of 2 separate experiments). (c) Representative time course
of [Ca2+]i in Fluo-4 AM loaded cells. NCX1 activity was probed in reverse
mode by monitoring the intracellular Ca2+ increase in response to a
stepwise reduction of external Na+ (140 mM, iso-osmotically replaced by
lithium). Fluorescence is reported as ratios (Fi/F0) of fluorescence counts
(Fi) relative to averaged baseline values before Na
+ removal (F0). (d) Ca
2+
responses (expressed as Δ%) were not significantly different between
Cav-3 WT and Cav-3 V82I transfected BHK-NCX1 cells (134.0 ± 6.4% vs
138.9 ± 8.7%, WT vs V82I respectively; P = 0.7). Each bar represents the
mean ± SEM of > 157 cells recorded in 3 different sessions.
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